ReviewFrontiers in bioscience (Elite edition)2012
Development and deployment of antigen arrays for investigation of B-cell fine specificity in autoimmune disease.
Review in Frontiers in bioscience (Elite edition), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 18 citations in OpenAlex.
- Increased inflammation and disease activity among current cigarette smokers with rheumatoid arthritis: a cross-sectional analysis of US veterans.Rheumatology (Oxford, England) · 2016Article
- Elevated IgA Plasmablast Levels in Subjects at Risk of Developing Rheumatoid Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2016Article
- Matrix metalloproteinase-10 is a target of T and B cell responses that correlate with synovial pathology in patients with antibiotic-refractory Lyme arthritis.Journal of autoimmunity · 2016Article
- Decade in review-technology: Technological advances transforming rheumatology.Nature reviews. Rheumatology · 2015Article
- Annexin A2 is a target of autoimmune T and B cell responses associated with synovial fibroblast proliferation in patients with antibiotic-refractory Lyme arthritis.Clinical immunology (Orlando, Fla.) · 2015Article
- Serology in the 21st century: the molecular-level analysis of the serum antibody repertoire.Current opinion in immunology · 2015Review
- Peptidylarginine deiminase 4 contributes to tumor necrosis factor α-induced inflammatory arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2014Article
- Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2014Article
- Testosterone is protective in the sexually dimorphic development of arthritis and lung disease in SKG mice.Arthritis and rheumatism · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Recent developments in proteomic technologies have enabled the high-throughput, multiplex measurement of large panels of antibodies in biological fluids of patients with immune-driven diseases. Antigen microarrays are increasingly being used to delineate the natural history of autoantibody formation and epitope spread, and thus gain insight into the pathogenesis of autoimmune diseases, as well as into host immunity and its shortcomings. Characterization of autoimmunity that precedes the onset of clinically apparent disease has the potential to guide disease prevention using either conventional immunosupression or novel, antigen-specific tolerizing therapies. In addition, autoantibody profiling has the potential to identify molecular subtypes of a disease, which could allow for prediction of disease outcomes such as severity, tissue damage, and response to therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.